Longitudinal analyses of anti-JCV antibody index for risk assessment of progressive multifocal leukoencephalopathy:

Multiple Sclerosis Journal – Experimental, Translational and Clinical

G. Kuesters²  T. Plavina²  M. Subramanyam²  A. Salmen³  R. Hoepner³  A. Chan³  R. Gold³  A.K. Trampe³  N. von Ahsen⁴ 

[1] Current address: Ambulantes Neurozentrum, Inselspital, Bern University Hospital, Bern, Switzerland;Biogen, Cambridge, MA, USA;Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Germany;Medizinisches Labor Bremen, Germany

关键词: Multiple sclerosis;    natalizumab;    PML;    biomarker;   

DOI  :  10.1177/2055217316630008

学科分类：医学（综合）

来源: Sage Journals

【 摘 要 】

Risk assessment for natalizumab-associated progressive multifocal leukoencephalopathy (Nat-PML) comprises the anti-JC virus (JCV) antibody index (AI). The anti-JCV AI was longitudinally determined in a natalizumab-treated MS cohort (Nat-MS, n = 468) and samples of Nat-PML patients (n = 15). In Nat-MS, the median AI was 0.8 (25th to 75th percentile, 0.2–2.8) with an intra-individual coefficient of variation (CV) of 9.8% (4.8–17.6). Patients with an AI ≤ 0.9 exhibited higher CV. The AI was higher (3.4 (3.1–3.6)) in samples before Nat-PML diagnosis than in seropositive Nat-MS (2.4 (1.0–3.4), n = 298, p = 0.010). AIs ≥ 3.0 were associated with a 14.5-fold (95% CI 2.3–90.4) increased PML risk (p = 0.002). Groups with an AI below 1.5 exhibit higher variability or even serostatus fluctuation. AI dynamics require further investigation.

【 授权许可】

CC BY-NC